Close Menu

Biocept NGS Breast Panel

Jun 18, 2019

Biocept has launched its second multi-gene liquid biopsy product, the Target Selector NGS Breast Panel, which is run on Thermo Fisher Scientific's Ion Torrent next generation sequencing platform and is designed to enable the detection and monitoring of actionable genomic biomarkers associated with breast cancer. The company said the test, which will be marketed to physicians and researchers, has shown over 99 percent sensitivity with at least 90 percent specificity in internal validations. 

Oct
21

Genomics is a key element in the potential of precision medicine to transform oncology. 

Oct
23

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries. 

Oct
24

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.

Nov
14
Sponsored by
Qiagen

This webinar will discuss some of the issues laboratories face when transitioning to next-generation sequencing, and the key features to be considered for a successful implementation in routine testing.